ProQR Therapeutics
PRQR
20 hedge funds and large institutions have $45M invested in ProQR Therapeutics in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 6 closing their positions.
3% more capital invested
Capital invested by funds: $43.6M → $45M (+$1.49M)
0.52% more ownership
Funds ownership: 38.07% → 38.59% (+0.52%)
13% less funds holding
Funds holding: 23 → 20 (-3)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$1.76M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$572K |
| 3 |
HP
Hikari Power
Tokyo,
Japan
|
+$106K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$45.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$1.04M |
| 2 |
Millennium Management
New York
|
-$539K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$196K |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$110K |
| 5 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
-$84.4K |
PRQR Hedge Fund Activity: Q1 2017 in Review
20 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2017, worth a combined $45M — up 3.4% from $43.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PRQR and 3 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 3 added.
The largest buyer was Artal Group, opening a new position worth an estimated $1.76M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.04M sold.
- 20 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2017, down from 23 in Q4 2016.
- Funds reported $45M of ProQR Therapeutics stock for Q1 2017, up 3.4% quarter-over-quarter.
- 3 funds opened new ProQR Therapeutics positions in Q1 2017 and 6 closed out, a net change of -3 holders.
- The largest ProQR Therapeutics buyer in Q1 2017 was Artal Group, an estimated $1.76M added.
- The largest ProQR Therapeutics seller in Q1 2017 was Baker Bros. Advisors, an estimated $1.04M sold.
Based on aggregated 13F filings for Q1 2017.